tiprankstipranks
vTv Therapeutics (DE:5VT0)
FRANKFURT:5VT0
Germany Market
5VT0
vTv Therapeutics
RESEARCH TOOLSreports

vTv Therapeutics (5VT0) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

5VT0 Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
vTv
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

5VT0 Stock 12 Month Forecast

Average Price Target

€50.37
▲(86.57% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for vTv Therapeutics in the last 3 months. The average price target is €50.37 with a high forecast of €57.69 and a low forecast of €36.17. The average price target represents a 86.57% change from the last price of €27.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"€12","35":"€35","58":"€58","23.5":"€23.5","46.5":"€46.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57.69441087,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€57.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.374970685,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€50.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.16664562,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€36.17</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,23.5,35,46.5,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27,29.36110852846154,31.72221705692308,34.083325585384614,36.44443411384616,38.80554264230769,41.16665117076923,43.52775969923077,45.888868227692306,48.24997675615384,50.611085284615385,52.97219381307692,55.333302341538456,{"y":57.69441087,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27,28.79807466807692,30.596149336153847,32.39422400423077,34.19229867230769,35.990373340384615,37.788448008461536,39.586522676538465,41.384597344615386,43.18267201269231,44.98074668076923,46.77882134884615,48.57689601692307,{"y":50.374970685,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27,27.705126586153845,28.41025317230769,29.115379758461536,29.820506344615385,30.52563293076923,31.230759516923076,31.93588610307692,32.64101268923077,33.346139275384616,34.05126586153846,34.756392447692306,35.46151903384615,{"y":36.16664562,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.8,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.5,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.4,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.8,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.4,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.6,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.2,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.2,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.8,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€57.69Average Price Target€50.37Lowest Price Target€36.17
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on DE:5VT0
Patrick Dolezal
LifeSci Capital
LifeSci Capital
€51.67
Buy
91.36%
Upside
Initiated
09/02/26
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (NASDAQ: KYMR) and vTv Therapeutics (NASDAQ: VTVT)
TD Cowen Analyst forecast on DE:5VT0
Ritu Baral
TD Cowen
TD Cowen
€57.69
Buy
113.68%
Upside
Reiterated
08/07/26
Analysts Conflicted on These NA Names: LATAM Airlines Group SA Sponsored ADR (NYSE: LTM), vTv Therapeutics (NASDAQ: VTVT) and Once Upon a Farm, PBC (NYSE: OFRM)
H.C. Wainwright Analyst forecast on DE:5VT0
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
€36.17
Buy
33.95%
Upside
Assigned
08/07/26
vTv Therapeutics price target lowered to $42 from $45 at H.C. WainwrightvTv Therapeutics price target lowered to $42 from $45 at H.C. Wainwright
Roth MKM Analyst forecast on DE:5VT0
Adam Walsh
Roth MKM
Roth MKM
€49.94
Buy
84.98%
Upside
Reiterated
08/07/26
vTv Therapeutics (VTVT) Gets a Buy from Roth MKM
BTIG Analyst forecast on DE:5VT0
Kambiz Yazdi
BTIG
BTIG
€49.08
Buy
81.79%
Upside
Reiterated
08/06/26
Analysts Offer Insights on NA Companies: vTv Therapeutics (NASDAQ: VTVT), TripAdvisor (NASDAQ: TRIP) and Caris Life Sciences, Inc. (NASDAQ: CAI)
Rodman & Renshaw Analyst forecast on DE:5VT0
Michael King
Rodman & Renshaw
Rodman & Renshaw
€57.69
Buy
113.68%
Upside
Initiated
06/30/26
vTv Therapeutics initiated with a Buy at Rodman & RenshawvTv Therapeutics initiated with a Buy at Rodman & Renshaw
Alliance Global Partners Analyst forecast on DE:5VT0
James Molloy
Alliance Global Partners
Alliance Global Partners
€47.36
Buy
75.41%
Upside
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (NASDAQ: VTVT), Waters (NYSE: WAT) and Alpha Teknova (NASDAQ: TKNO)
Evercore ISI Analyst forecast on DE:5VT0
Michael DiFiore
Evercore ISI
Evercore ISI
€37.89
Buy
40.33%
Upside
Initiated
03/12/26
vTv Therapeutics initiated with an Outperform at Evercore ISIvTv Therapeutics initiated with an Outperform at Evercore ISI
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on DE:5VT0
Patrick Dolezal
LifeSci Capital
LifeSci Capital
€51.67
Buy
91.36%
Upside
Initiated
09/02/26
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (NASDAQ: KYMR) and vTv Therapeutics (NASDAQ: VTVT)
TD Cowen Analyst forecast on DE:5VT0
Ritu Baral
TD Cowen
TD Cowen
€57.69
Buy
113.68%
Upside
Reiterated
08/07/26
Analysts Conflicted on These NA Names: LATAM Airlines Group SA Sponsored ADR (NYSE: LTM), vTv Therapeutics (NASDAQ: VTVT) and Once Upon a Farm, PBC (NYSE: OFRM)
H.C. Wainwright Analyst forecast on DE:5VT0
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
€36.17
Buy
33.95%
Upside
Assigned
08/07/26
vTv Therapeutics price target lowered to $42 from $45 at H.C. WainwrightvTv Therapeutics price target lowered to $42 from $45 at H.C. Wainwright
Roth MKM Analyst forecast on DE:5VT0
Adam Walsh
Roth MKM
Roth MKM
€49.94
Buy
84.98%
Upside
Reiterated
08/07/26
vTv Therapeutics (VTVT) Gets a Buy from Roth MKM
BTIG Analyst forecast on DE:5VT0
Kambiz Yazdi
BTIG
BTIG
€49.08
Buy
81.79%
Upside
Reiterated
08/06/26
Analysts Offer Insights on NA Companies: vTv Therapeutics (NASDAQ: VTVT), TripAdvisor (NASDAQ: TRIP) and Caris Life Sciences, Inc. (NASDAQ: CAI)
Rodman & Renshaw Analyst forecast on DE:5VT0
Michael King
Rodman & Renshaw
Rodman & Renshaw
€57.69
Buy
113.68%
Upside
Initiated
06/30/26
vTv Therapeutics initiated with a Buy at Rodman & RenshawvTv Therapeutics initiated with a Buy at Rodman & Renshaw
Alliance Global Partners Analyst forecast on DE:5VT0
James Molloy
Alliance Global Partners
Alliance Global Partners
€47.36
Buy
75.41%
Upside
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (NASDAQ: VTVT), Waters (NYSE: WAT) and Alpha Teknova (NASDAQ: TKNO)
Evercore ISI Analyst forecast on DE:5VT0
Michael DiFiore
Evercore ISI
Evercore ISI
€37.89
Buy
40.33%
Upside
Initiated
03/12/26
vTv Therapeutics initiated with an Outperform at Evercore ISIvTv Therapeutics initiated with an Outperform at Evercore ISI
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
AXGNAxoGen
ATECAlphatec Holdings
CABACabaletta Bio
ONCBeOne Medicines
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering vTv Therapeutics

3 Months
Emily BodnarH.C. Wainwright
Success Rate
4/10 ratings generated profit
40%
Average Return
+11.81%
Copying Emily Bodnar's trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +11.81% per trade.
1 Year
James MolloyAlliance Global Partners
Success Rate
3/5 ratings generated profit
60%
Average Return
+39.32%
Copying James Molloy's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +39.32% per trade.
2 Years
James MolloyAlliance Global Partners
Success Rate
3/5 ratings generated profit
60%
Average Return
+35.38%
Copying James Molloy's trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +35.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

5VT0 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
7
4
6
6
6
Buy
5
3
3
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
7
9
7
7
In the current month, 5VT0 has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 5VT0 average Analyst price target in the past 3 months is 50.37.
Each month's total comprises the sum of three months' worth of ratings.

5VT0 Financial Forecast

5VT0 Earnings Forecast

Next quarter’s earnings estimate for 5VT0 is -€1.00 with a range of -€1.11 to -€0.87. The previous quarter’s EPS was -€0.91. 5VT0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 5VT0 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 5VT0 is -€1.00 with a range of -€1.11 to -€0.87. The previous quarter’s EPS was -€0.91. 5VT0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 5VT0 has Performed in-line its overall industry.

5VT0 Sales Forecast

Next quarter’s sales forecast for 5VT0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 5VT0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 5VT0 has Performed in-line its overall industry.
Next quarter’s sales forecast for 5VT0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 5VT0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 5VT0 has Performed in-line its overall industry.

5VT0 Stock Forecast FAQ

What is DE:5VT0’s average 12-month price target, according to analysts?
Based on analyst ratings, vTv Therapeutics’s 12-month average price target is 50.37.
    What is DE:5VT0’s upside potential, based on the analysts’ average price target?
    vTv Therapeutics has 86.57% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is vTv Therapeutics a Buy, Sell or Hold?
          vTv Therapeutics has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is vTv Therapeutics’s share price target?
            The average share price target for vTv Therapeutics is 50.37. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €57.69 ,and the lowest forecast is €36.17. The average share price target represents 86.57% Increase from the current price of €27.
              What do analysts say about vTv Therapeutics?
              vTv Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of vTv Therapeutics?
                To buy shares of DE:5VT0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.